Table 1.
Comparative table of the patients receiving versus not receiving augmentation therapy
| Augmented group | Non-augmented group | P | |
|---|---|---|---|
| n (%) | 124 (76%) | 40 (24%) | |
| Age in yearsa | 61.3 (0.7) | 56.1 (1.9) | 0.01 |
| Age at diagnosis of AATDa | 46.4 (0.8) | 44.5 (1.8) | 0.32 |
| % Female gender | 52.4% | 50% | 0.26 |
| % White race | 95.2 | 90% | 0.58 |
| % Ex-smokers | 84.7% | 62.5% | <0.001 |
| % Current smokers | 0% | 5% | 0.06 |
| Number of years of smokinga | 19.4 (0.9) | 17.3 (1.4) | 0.2 |
| Exposure to dust or fumes at work | 56.5% | 45% | 0.21 |
| Dyspnea | 91.9% | 75% | 0.004 |
| Asthma | 25% | 10% | 0.04 |
| COPD (emphysema) | 37.1% | 15% | 0.009 |
| Bronchiectasis | 12.1% | 5% | 0.25 |
| Pneumonia | 21% | 12.5% | 0.23 |
| Pneumothorax | 3.2% | 2.5% | 1 |
| Hepatitis | 2.4% | 7.5% | 0.16 |
| Cirrhosis | 0% | 5% | 0.06 |
| FHx of AATD | 63.7% | 67.5% | 0.66 |
| FHx of emphysema | 40.3% | 47.5% | 0.42 |
| Inhaled bronchodilator | 86.3% | 55% | <0.001 |
| Inhaled corticosteroid | 59.7% | 45% | 0.1 |
| Inhaled anticholinergics | 6.5% | 0% | 0.2 |
| Oral bronchodilators | 11.3% | 5% | 0.24 |
| Systemic corticosteroids | 7.3% | 2.5% | 0.3 |
| Theophylline | 10.5% | 5% | 0.3 |
| Oxygen therapy | 50.8% | 12.5% | <0.001 |
| Baseline FEV1 (L/m)a | 1.4 (0.1) | 2.4 (0.2) | <0.001 |
| Baseline FEV1 (% of predicted)a | 43 (2) | 77 (5) | <0.001 |
| Duration of follow-up (months)a | 43.6 (3.2) | 35.7 (3.2) | 0.19 |
| Number of spirometriesb | 2 | 2 | 0.88 |
| 1st spirometry after 2004c | 50% | 57.5% | 0.41 |
| Deceased patients | 8 (6.4%) | 1 (2.5%) | 0.46 |
Abbreviation: AATD, alpha-1 antitrypsin deficiency; FHx, family history.
Notes:
a
Continuous values are provided as mean (± SE);
b
Median number of spirometries;
c
Percentage of patients in whom the first spirometry was performed after January 1, 2004.